How can citrus bergamia (bergamot) extract be used to lower LDL‑C, including recommended dose, expected reduction, monitoring, and contraindications?

Citrus Bergamia (Bergamot) Extract for LDL-Cholesterol Lowering

Bergamot extract is a reasonable adjunctive nutraceutical option for mild-to-moderate LDL-C elevation, typically reducing LDL-C by 10-15% at doses of 150 mg flavonoids daily, though it should not replace statin therapy in high-risk patients requiring guideline-directed medical therapy.

Guideline Context: When Bergamot May Be Considered

Current cardiovascular guidelines do not specifically endorse bergamot extract, but they do acknowledge plant stanols/sterols and dietary approaches as adjuncts to LDL-lowering therapy 1, 2. The 2022 ACC Expert Consensus recognizes nonstatin therapies for patients unable to achieve LDL-C goals, though bergamot is not specifically listed among FDA-approved agents 3.

Key principle: For low-risk adults (0-1 risk factors) with LDL-C around 100 mg/dL, no pharmacologic therapy is indicated as this is well below the 160 mg/dL intervention threshold 4. Bergamot would be considered only when LDL-C rises above goal for the patient's risk category.

Clinical Evidence for Bergamot Extract

Expected LDL-C Reduction

Multiple randomized controlled trials demonstrate consistent lipid-lowering effects:

• 11.5% LDL-C reduction after 4 months with 150 mg/day flavonoids in moderately hypercholesterolemic subjects 5
• 19.6% LDL-C reduction (from 4.6 to 3.7 mmol/L) after 6 months with 150 mg/day flavonoids 6
• Significant reductions in total cholesterol (8.8%), LDL-C (11.5%), and triglycerides, with trending HDL-C increase (5.5%) 5

Additional Metabolic Benefits

Beyond LDL-C lowering, bergamot extract demonstrates:

• Reduction in atherogenic small dense LDL particles (LDL-3, -4, -5 subfractions decreased significantly) 6
• Decreased oxidized LDL by 2.0% with increased paraoxonase-1 activity by 6.5% 5
• Improved glucose metabolism with significant reductions in fasting plasma glucose 7, 8
• Reduced inflammatory markers including hs-CRP and TNF-α 9
• Decreased carotid intima-media thickness from 1.2 to 0.9 mm over 6 months 6

Recommended Dosing

Standard dose: 150 mg of standardized flavonoids daily 5, 6, 9

The flavonoid composition typically includes:

• 16% neoeriocitrin
• 47% neohesperidin
• 37% naringin 6

Higher doses (up to 400 mg/day) have been studied with good tolerability 7, though 150 mg appears to be the most evidence-based dose for lipid management.

Mechanism of Action

Bergamot extract works through multiple pathways:

• AMPK activation (phosphorylation at threonine 172), which reduces intracellular cholesterol and triglyceride synthesis 7
• Downregulation of lipogenic genes including SREBF1c, SREBF2, ACACA, SCD1, HMGCR, and FASN 7
• Inhibition of HMG-CoA reductase (similar mechanism to statins, but weaker effect) 10

Appropriate Patient Selection

Consider bergamot extract for:

• Mild hypercholesterolemia (LDL-C 160-190 mg/dL or 4.1-4.9 mmol/L) in low-risk patients who prefer nutraceutical approaches 6
• Statin-intolerant patients experiencing side effects from conventional therapy 6, 10
• Adjunctive therapy in patients not achieving LDL-C goals despite lifestyle modifications but not yet requiring intensive pharmacotherapy 9, 11
• Metabolic syndrome patients with combined dyslipidemia, insulin resistance, and elevated inflammatory markers 8, 9

Do NOT use bergamot as monotherapy for:

• High-risk patients with established ASCVD requiring LDL-C <70 mg/dL—these patients need statin therapy per guidelines 2, 12
• Very high baseline LDL-C (≥190 mg/dL)—pharmacologic therapy with statins is indicated 12, 4
• Patients with 10-year ASCVD risk ≥7.5%—statin therapy is guideline-recommended 13

Monitoring Parameters

Baseline assessment:

• Fasting lipid panel (TC, LDL-C, HDL-C, triglycerides, non-HDL-C) 5, 6
• Liver enzymes (ALT, AST, GGT) 7
• Fasting glucose 7, 8

Follow-up monitoring:

• Lipid panel at 8-12 weeks to assess response 5, 9
• Liver enzymes if baseline abnormalities present 7
• Re-assess at 4-6 months for sustained effect 6, 11

Safety Profile and Contraindications

Safety data:

• Well-tolerated with no significant adverse effects reported in clinical trials 5, 6, 9
• No changes in hepatic or renal function markers during studies 5
• No drug-drug interactions specifically documented, though theoretical concerns exist with medications metabolized similarly to citrus flavonoids 10

Contraindications and cautions:

• Pregnancy and lactation—no safety data available; avoid use 10
• Patients on multiple medications—potential for flavonoid interactions with CYP450 enzymes (theoretical concern) 10
• Severe hepatic impairment—use caution given lack of data 10

Critical Limitations and Caveats

Evidence gaps:

• No cardiovascular outcomes data—unlike statins, bergamot has not been studied for reduction in MI, stroke, or cardiovascular death 10
• Relatively short study durations—most trials are 3-6 months; long-term efficacy and safety unknown 5, 6
• Small sample sizes—largest trials include 60-90 participants 5, 8, 9

Recent negative trial:

One 2025 study found no significant LDL-C lowering with a complex formulation containing bergamot extract, plant sterols, artichoke extract, and hydroxytyrosol, suggesting potential ingredient interactions may interfere with efficacy 14. This highlights that combination products may not be superior to bergamot alone.

Comparison to guideline-recommended therapies:

• Plant stanols/sterols (2 g/day) are specifically recommended by ACC/AHA guidelines and reduce LDL-C by similar amounts 1, 2
• Ezetimibe (FDA-approved) reduces LDL-C by 18% as monotherapy with proven cardiovascular outcomes data 3
• Statins remain the cornerstone of LDL-lowering therapy with extensive outcomes data 2, 12, 13

Practical Implementation Algorithm

Step 1: Determine patient's ASCVD risk category and LDL-C goal 12, 13, 4

Step 2: If patient is:

• Low-risk with LDL-C <160 mg/dL: Lifestyle modification only; no bergamot needed 4
• Low-risk with LDL-C 160-189 mg/dL: Consider bergamot 150 mg/day as alternative to immediate statin therapy 4, 6
• Moderate-risk with LDL-C 130-160 mg/dL: Lifestyle changes first; bergamot may be adjunctive 12, 9
• High-risk or LDL-C ≥190 mg/dL: Statin therapy required per guidelines; bergamot not appropriate as monotherapy 12, 13, 4

Step 3: If bergamot is appropriate, prescribe 150 mg standardized flavonoids daily 5, 6

Step 4: Recheck lipids at 8-12 weeks 5, 9

Step 5: If LDL-C goal not achieved, escalate to guideline-directed pharmacotherapy (statin ± ezetimibe) 3, 13

Bottom Line

Bergamot extract at 150 mg flavonoids daily can reduce LDL-C by approximately 10-15% in patients with mild hypercholesterolemia, but it lacks cardiovascular outcomes data and should not replace statin therapy in patients who meet guideline criteria for pharmacologic treatment 5, 6, 10. It is most appropriately used in low-risk patients with borderline LDL-C elevation who prefer nutraceutical approaches or as adjunctive therapy in statin-intolerant patients 6, 10. The 2018/2019 ACC/AHA guidelines emphasize that clinician-patient risk discussions should guide treatment decisions, and bergamot may be discussed as part of a comprehensive approach that prioritizes lifestyle modification and evidence-based pharmacotherapy when indicated 13.